Background mRNA vaccines hold great potential as therapeutic techniques against viral
infections due to their efficacy, safety, and large-scale production. mRNA vaccines offer …

Abstract mRNA vaccines have tremendous potential to fight against cancer and viral
diseases due to superiorities in safety, efficacy and industrial production. In recent decades …

Suboptimal childhood vaccination uptake results in disease outbreaks, and in developed
countries is largely attributable to parental choice. To inform evidence-based interventions …

With very few adjuvants currently being used in marketed human vaccines, a critical need
exists for novel immunopotentiators and delivery vehicles capable of eliciting humoral …

Over the past decade developments in the field of biotechnology have led to the cloning,
characterization, and commercial availability of many clinically useful proteins and peptides …

With the exception of the provision of clean water supplies, vaccination remains the most
successful public health intervention strategy for the control of infectious diseases. However …

Concern over vaccine safety has been a major determinant of immunization policy—from
passage of the Biologics Control Act in 1902 to the recent American Academy of Pediatrics …

Macrophages that react against pathogenic organisms can also be activated with artificial
nanometric units consisting of gold nanoparticles (Au NPs) with a peptide coating. Using …

As immunizations successfully reduce the incidence of their target diseases, the vaccine
community needs to evolve and recognize the increased relative prominence of vaccine …

Adjuvants are of critical value in vaccine development as they act on enhancing
immunogenicity of antigen and inducing long‐lasting immunity. However, there are only a …